Autoimmune diseases were so far considered to arise when the immune system mistakenly attacks the body’s own tissues. Recent researches have provided enough data to show that it is not the antibodies generated against native cells that cause autoimmune diseases, but it is the antibodies generated in the body against infectious agents and ‘alien proteins’ that cause those diseases. This new understanding is bringing a great paradigm shift in the diagnosis and treatment of so-called autoimmune diseases. It also underscores the correctness of miasm concept of chronic diseases in homeopathy, which was so far considered unscientific by modern scientific community. Now it is obvious that what Hahnemann called ‘miasmatic diseases’, and what modern medicine calls ‘autoimmune diseases’ belong to the same class.
MIT concept explains the homeopathy concept of ‘miasms’ in terms of chronic disease dispositions caused by antibodies and deformed proteins. This explanation helps us to approach those so-called AUTO IMMUNE DISEASES from a new angle.
Look into the exhaustive list of diseases included in the class of autoimmune diseases which are actually ‘chronic diseases caused by off-target actions of antibodies. Kindly go through the complete list of autoimmune diseases, and the modern understanding of their relationships with infectious diseases, to realise the real magnitude of ‘anti-body mediated’ diseases or ‘miasmatic’ diseases we encounter in our day today clinical practice.
While introducing the concept of miasms, Hahnemann was actually trying to explain the role of residual effects of acute infectious diseases in precipitating chronic disease conditions. His focus was on infectious ITCH/LEPROSY, SYPHILIS and HPV-GONORRHOEA complex, which were most widespread around his place during his time.
Hahnemann, from his practical experience of applying ‘Similia Similibus Curentur’, came to the conclusion that complete cure is not possible using SIMILIMUM only, if such a similimum is selected using totality of currently existing symptoms only, without considering the ‘miasms’ or residual effects of previous acute infectious diseases.
Even though Hahnemann could rightly observe the role of miasms or residual effects of infectious diseases in the causation as well as the curative process of chronic diseases, he could not explain the exact biological mechanism by which this phenomenon works. This failure was due to the primitive state scientific knowledge available during his period, which later led to various kinds unscientific and “dynamic” interpretations by his “disciples” and “followers” which continue till the present day.
Using the scientific knowledge already available now, I have been trying to explore the exact molecular mechanism by which residual effects of acute infectious diseases contribute to the development of chronic disease conditions, which Hahnemann called ‘miasms’.
It is common knowledge that antibodies are generated in our body against infectious agents or proteins that are alien to our genetic codes. Even after infectious disease is over, these antibodies remain in our body for long periods, even for whole life in certain cases.
Since antibodies are native globulin proteins that have undergone deformation by interacting with alien proteins or infectious agents, they can themselves behave as aliens in the organism and produce pathological inhibitions by binding to various off-target biological molecules. Such molecular inhibitions caused by antibodies are the real molecular level villains playing behind various chronic diseases such as AUTOIMMUNE DISEASES, PROTEINOPATHIES, AMYLOID DISEASES AND PRION DISEASES.
Hahnemann called these phenomena of chronic residual effects of antibodies as MIASMS.
See, how Hahnemann’s concept of chronic diseases relating it with infectious diseases, paves the way for a scientific understanding of a whole class of grave diseases, and developing of a whole new range of therapeutic agents and techniques to combat them.
Hahnemann’s observations of chronic diseases, relating it with infectious diseases, would have been a revolutionary event in medical history, had anybody- be it hahnemann himself, his followers or scientists- taken up the task of explaining it in scientific terms.
Had anybody asked the question how an infectious disease can cause life-long residual effects in the organism even after the infection is over, everything would have been clear. It would have been obvious that infectious agents can produce life-long residual effects in the form of chronic diseases only through ANTIBODIES generated in the body against infectious agents.
Such a realisation would have helped medical as well as scientific community to view antibodies from a different perspective- as causative agents of diverse types of chronic diseases- over and above their role as defense molecules.
The pathophysiology of autoimmune diseases is multifaceted, involving genetic predispositions, environmental factors, and immune system dysregulation. Infectious agents have been implicated as potential triggers for many autoimmune conditions, either through molecular mimicry, bystander activation, or direct tissue damage.
Antibodies generated against infectious agents can become causative agents of autoimmune diseases through mechanisms such as molecular mimicry, epitope spreading, bystander activation, and cryptic antigen expression. The relationship between infections and autoimmune diseases is complex and multifactorial. Antibodies generated against infectious agents can become pathogenic through various mechanisms, including molecular mimicry, epitope spreading, bystander activation, and cryptic antigen expression. Understanding these mechanisms is crucial for developing targeted therapies to prevent and treat autoimmune diseases triggered by infections.
Ongoing research is essential to further elucidate these mechanisms and identify specific molecular targets for intervention. By improving our understanding of the interplay between infections and autoimmunity, we can better manage and potentially prevent the onset of autoimmune diseases in susceptible individuals.
Research into the cross-reactivity between microbial antigens and human tissues can help identify specific epitopes that lead to autoimmune responses. Advanced techniques like mass spectrometry and bioinformatics are used to identify shared epitopes.
Certain genetic backgrounds may predispose individuals to autoimmune diseases following infections. For instance, HLA haplotypes are known to influence the likelihood of developing autoimmune conditions after exposure to specific pathogens.
While vaccines are crucial for preventing infectious diseases, there is ongoing research to ensure that vaccine components do not inadvertently trigger autoimmune responses in susceptible individuals. Understanding the molecular mechanisms involved can help design safer vaccines.
Immunomodulation: Treatments that modulate the immune response, such as corticosteroids, immunoglobulins, and biologics, can help manage autoimmune diseases triggered by infections.
Antiviral Therapies: In cases where viral infections are implicated in autoimmunity, antiviral drugs can reduce viral load and potentially decrease autoimmune triggers.
The interplay between infectious agents and the immune system is intricate and can lead to the development of autoimmune diseases through various mechanisms. Identifying and understanding these mechanisms is crucial for developing targeted therapies and preventive measures. Continued research is essential to further elucidate the complex relationships between infections and autoimmunity, improving patient outcomes and reducing the burden of these diseases.
By advancing our knowledge in this field, we can enhance diagnostic accuracy, create more effective treatments, and potentially prevent the onset of autoimmune diseases in at-risk populations. This integrated approach will be pivotal in managing and mitigating the impacts of autoimmune diseases globally.
The human microbiome plays a crucial role in the regulation of the immune system. Dysbiosis, or imbalances in the microbial communities, can influence the development of autoimmune diseases. Understanding how the microbiome interacts with pathogens and the immune system is essential for developing new therapeutic strategies.
Environmental factors such as diet, toxins, and stress can modulate the immune response and influence susceptibility to autoimmune diseases. Identifying these factors can help in creating preventive measures and personalized treatments.
Chronic infections and their role in autoimmunity necessitate long-term monitoring of patients to identify and manage autoimmune responses early. This includes regular screenings and proactive management of infections known to trigger autoimmunity.
Autoimmune responses can sometimes target cancer cells, leading to paraneoplastic syndromes. Understanding the dual role of the immune system in cancer and autoimmunity can help in developing immunotherapies that minimize autoimmune side effects while effectively targeting cancer cells.
Identifying biomarkers that predict the development of autoimmune diseases following infections can help in early diagnosis and intervention. Biomarkers can include specific antibodies, cytokine profiles, and genetic markers.
Tailoring treatments based on an individual’s genetic makeup, infection history, and immune profile can improve outcomes and reduce adverse effects. Precision medicine approaches can help in developing targeted therapies that address the underlying causes of autoimmunity.
Developing vaccines that prevent infections known to trigger autoimmune diseases can be a powerful preventive measure. Additionally, ensuring that vaccines do not inadvertently trigger autoimmune responses in susceptible individuals is crucial.
Mechanisms of Antibody-Mediated Autoimmunity
1. Molecular Mimicry
Description: Molecular mimicry occurs when antibodies or T cells generated against an infectious agent cross-react with self-antigens due to structural similarities between the pathogen and host tissues.
Examples:
Rheumatic Fever: Antibodies against Streptococcus pyogenes cross-react with cardiac myosin and other heart tissues, leading to rheumatic heart disease.
Guillain-Barré Syndrome: Antibodies against Campylobacter jejuni lipo-oligosaccharides cross-react with gangliosides in peripheral nerves, causing demyelination.
2. Epitope Spreading
Description: During an infection, the immune response initially targets specific epitopes on a pathogen. Over time, the immune response can expand to target other epitopes, including self-antigens released during tissue damage.
Examples:
Systemic Lupus Erythematosus (SLE): Infections can lead to the release of nuclear material from damaged cells, promoting the development of antibodies against DNA and other nuclear components.
3. Bystander Activation
Description: Infections can induce a strong inflammatory response, activating antigen-presenting cells (APCs) and bystander T cells, including self-reactive T cells that were previously non-pathogenic.
Examples:
Type 1 Diabetes: Viral infections can trigger the release of pancreatic antigens, activating autoreactive T cells and leading to the destruction of insulin-producing beta cells.
4. Cryptic Antigen Expression
Description: Infections can cause the expression of previously hidden (cryptic) self-antigens, making them targets for the immune system.
Examples:
Multiple Sclerosis: Viral infections in the central nervous system can expose myelin antigens to the immune system, leading to an autoimmune response against myelin.
5. Superantigen Activation
Description: Certain pathogens produce superantigens that can non-specifically activate a large number of T cells, including self-reactive T cells, leading to an autoimmune response.
Examples:
Kawasaki Disease: Superantigens from bacterial infections (e.g., Staphylococcus aureus) are believed to trigger an intense immune response that affects blood vessels.
6. Molecular Mimicry with Post-Translational Modifications
Description: Some pathogens induce post-translational modifications of host proteins, making them appear foreign to the immune system, leading to an autoimmune response.
Examples:
Rheumatoid Arthritis: Epstein-Barr Virus (EBV) and other infections can induce citrullination of proteins, leading to the development of anti-citrullinated protein antibodies (ACPA).
7. Immune Complex Deposition
Chronic infections can lead to the formation of immune complexes (antigen-antibody complexes) that deposit in various tissues, causing inflammation and tissue damage.
Examples:
Systemic Lupus Erythematosus (SLE): Chronic viral infections can result in the persistent formation of immune complexes that deposit in the kidneys, joints, and skin, contributing to the characteristic symptoms of SLE.
Monoclonal antibodies that target specific components of the immune system can effectively treat autoimmune diseases triggered by infections. Reducing viral load through antiviral treatments can decrease the risk of autoimmune responses in chronic viral infections. Treatments that modulate the immune response, such as corticosteroids, immunoglobulins, and biologics, can help manage autoimmune diseases triggered by infections.
The relationship between infections and autoimmune diseases is multifaceted and involves complex interactions between genetic, environmental, and immune factors. Understanding these mechanisms is crucial for developing effective prevention, diagnosis, and treatment strategies.
Continued research into the molecular and cellular mechanisms underlying infection-induced autoimmunity will provide deeper insights and lead to more effective interventions. By integrating knowledge from immunology, genetics, microbiology, and clinical medicine, we can improve patient outcomes and reduce the burden of autoimmune diseases globally.
Some Examples of Specific Infectious Agents and Associated Autoimmune Diseases
1. Epstein-Barr Virus (EBV)
Associated Diseases: Multiple Sclerosis, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Mechanisms: Molecular mimicry, epitope spreading
2. Hepatitis C Virus (HCV)
Associated Diseases: Cryoglobulinemia, Sjögren’s Syndrome
Mechanisms: Molecular mimicry, bystander activation
3. Campylobacter jejuni
Associated Diseases: Guillain-Barré Syndrome
Mechanisms: Molecular mimicry
4. Helicobacter pylori
Associated Diseases: Immune Thrombocytopenic Purpura (ITP), Autoimmune Gastritis
Mechanisms: Molecular mimicry, bystander activation
5. Coxsackievirus
Associated Diseases: Type 1 Diabetes, Myocarditis
Mechanisms: Molecular mimicry, bystander activation
6. Human Immunodeficiency Virus (HIV)
Associated Diseases: Immune Thrombocytopenic Purpura (ITP), Vasculitis
Mechanisms: Bystander activation, cryptic antigen expression
7. Streptococcus pyogenes
Associated Diseases: Rheumatic Fever, Post-streptococcal Glomerulonephritis
Mechanisms: Molecular mimicry
8. Cytomegalovirus (CMV)
Associated Diseases: Systemic Lupus Erythematosus, Multiple Sclerosis
Mechanisms: Molecular mimicry, bystander activation
9. Human T-Cell Lymphotropic Virus (HTLV-1)
Associated Diseases: Adult T-Cell Leukemia/Lymphoma, HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)
Mechanisms: Molecular mimicry, bystander activation
10. Parvovirus B19
Associated Diseases: Systemic Lupus Erythematosus, Rheumatoid Arthritis
Mechanisms: Molecular mimicry, epitope spreading
11. Mycoplasma pneumoniae
Associated Diseases: Stevens-Johnson Syndrome, Guillain-Barré Syndrome
Mechanisms: Molecular mimicry, superantigen activation
12. Borrelia burgdorferi (Lyme Disease)
Associated Diseases: Lyme Arthritis, Chronic Lyme Disease
Mechanisms: Molecular mimicry, bystander activation
13. Varicella-Zoster Virus (VZV)
Associated Diseases: Giant Cell Arteritis, Multiple Sclerosis
Mechanisms: Molecular mimicry, bystander activation
14. Influenza Virus
Associated Diseases: Guillain-Barré Syndrome, Myocarditis
Mechanisms: Molecular mimicry, bystander activation
15. Enterovirus
Associated Diseases: Type 1 Diabetes, Myocarditis
Mechanisms: Molecular mimicry, bystander activation
17. Hepatitis B Virus (HBV)
Associated Diseases: Polyarteritis Nodosa, Glomerulonephritis
Mechanisms: Immune complex deposition, molecular mimicry
19. Cytomegalovirus (CMV)
Associated Diseases: Systemic Lupus Erythematosus, Guillain-Barré Syndrome
Mechanisms: Molecular mimicry, bystander activation
20. Chlamydia pneumoniae
Associated Diseases: Reactive Arthritis, Atherosclerosis
Mechanisms: Molecular mimicry, immune complex deposition
21. Rubella Virus
Associated Diseases: Chronic Arthritis, Type 1 Diabetes
Mechanisms: Molecular mimicry, bystander activation
22. Herpes Simplex Virus (HSV)
Associated Diseases: Erythema Multiforme, Autoimmune Encephalitis
Mechanisms: Molecular mimicry, epitope spreading
Our knowledge regarding the relationship between so-called autoimmune diseases and infectious diseases is not complete yet. It is still evolving. There are many autoimmune diseases remaining to be explained from this angle. Not only infectious diseases, but any ‘alien protein’ entering the body such as vaccines, snake bites, scorpion bites, insect bites, various allergens etc also can generate antibodies, and ultimately lead to autoimmune diseases through their off target actions. Even there may be endogenous alien proteins also, such as proteins synthesized by mutated genes in cancer cells in our body. It means, the topic of autoimmunity or miasms is very vast. A lot of research have to done on this line for emerging better undurstanding of the phenomenon.
REDEFINING HOMEOPATHY 
Leave a comment